The best Side of HOIPIN-1
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis or poly